Home Journal Club	FAQ My Amedeo About Tranquillis Services	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

HIV Infection

Free Subscription Articles published in Vaccine Retrieve available abstracts of 100 articles: HTML format Text format

Single Articles

February 2010
1. YASHIMA S , Yoshizaki S, Shinoda K, Yoshida A, et al
   Co-administration of viral vector-based vaccines suppresses antigen-specific effector CD8 T cells.
   Vaccine. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
2. MUTHUMANI K , Lambert VM, Kawalekar O, Heller R, et al
   Anti-cancer activity of the HIV accessory molecule viral protein R (Vpr): Delivery as a DNA expression plasmid or biologically active peptides.
   Vaccine. 2010;28:2005-2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
3. STARODUBOVA E , Boberg A, Ivanov A, Latyshev O, et al
   Potent cross-reactive immune response against the wild-type and drug-resistant forms of HIV reverse transcriptase after the chimeric gene immunization.
   Vaccine. 2010;28:1975-1986.
   PubMed     Text format     Related articles    Abstract available
   
   
   
4. VALENTIN A , von Gegerfelt A, Rosati M, Miteloudis G, et al
   Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit.
   Vaccine. 2010;28:1962-74.
   PubMed     Text format     Related articles    Abstract available
   
   
   
5. LEMIALE F , Asefa B, Ye D, Chen C, et al
   An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization.
   Vaccine. 2010;28:1952-1961.
   PubMed     Text format     Related articles    Abstract available
   
   
   
6. KRAYNYAK KA , Kutzler MA, Cisper NJ, Khan AS, et al
   Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques.
   Vaccine. 2010;28:1942-1951.
   PubMed     Text format     Related articles    Abstract available
   
   
   
7. YIN J , Dai A, Shen A, Lecureux J, et al
   Viral reservoir is suppressed but not eliminated by CD8 vaccine specific lymphocytes.
   Vaccine. 2010;28:1924-1931.
   PubMed     Text format     Related articles    Abstract available
   
   
   
8. VAINE M , Wang S, Hackett A, Arthos J, et al
   Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.
   Vaccine. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
9. KRASHIAS G , Simon K, Wegmann F, Kok WL, et al
   Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer.
   Vaccine. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   January 2010
10. AMENDOLA A , Pariani E, Vigano A, Erba P, et al
    Influenza surveillance in a cohort of HIV-infected children and adolescents immunized against seasonal influenza.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
11. HARANDI AM , Medaglini D, Shattock RJ
    Vaccine adjuvants: A priority for vaccine research.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
12. VAN-DUNEM JC , Alencar LC, Rodrigues LC, Albuquerque MD, et al
    Sensitivity and specificity of BCG scar reading among HIV-infected children.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
13. SEGAT L , Brandao LA, Guimaraes RL, Pontillo A, et al
    Polymorphisms in innate immunity genes and patients response to dendritic cell-based HIV immuno-treatment.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
14. ASEFA B , Korokhov N, Lemiale F
    Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity.
    Vaccine. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    December 2009
15. BRAVE A , Johansson U, Hallengard D, Heidari S, et al
    Induction of HIV-1-specific cellular and humoral immune responses following immunization with HIV-DNA adjuvanted with activated apoptotic lymphocytes.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
16. DHALLA S , Poole G, Singer J, Patrick D, et al
    Cognitive factors and willingness to participate in an HIV vaccine trial among HIV-negative injection drug users.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
17. ABDEL-MOTAL UM , Wang S, Awad A, Lu S, et al
    Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopes.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
18. MANGTANI P , Mulholland K, Madhi SA, Edmond K, et al
    Haemophilus influenzae type b disease in HIV-infected children: A review of the disease epidemiology and effectiveness of Hib conjugate vaccines.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
19. POTSCH DV , Oliveira ML, Ginuino C, Miguel JC, et al
    High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
20. VAN ROMPAY KK , Abel K, Earl P, Kozlowski PA, et al
    Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: Attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
21. PESSOA SD , Miyamoto M, Ono E, Gouvea AF, et al
    Persistence of vaccine immunity against hepatitis B virus and response to revaccination in vertically HIV-infected adolescents on HAART.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2009
22. GANGULY S , Liu J, Pillai VB, Mittler RS, et al
    Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: Different effects on cellular and humoral immunity.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
23. GOLDSTEIN G , Chiccas JJ 2nd
    A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
24. MAST TC , Kierstead L, Gupta SB, Nikas AA, et al
    International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
25. NEWMAN PA , Roungprakhon S, Tepjan S, Yim S, et al
    Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2009
26. SELLHORN G , Caldwell Z, Mineart C, Stamatatos L, et al
    Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
27. BRIDGEMAN A , Roshorm Y, Lockett LJ, Xu ZZ, et al
    Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
28. HUNTER Z , Smyth HD, Durfee P, Chackerian B, et al
    Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
29. RANGANATHAN UD , Larsen MH, Kim J, Porcelli SA, et al
    Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8(+) T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2009
30. SIM MS , Cumberland WG, Duan N, Bryson YJ, et al
    Modeling vertical transmission of HIV: Imperfect vaccines can be of benefit.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
31. BELAUNZARAN PF , Garcia-Leon ML, Wong-Chew RM, Villasis-Keever A, et al
    Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
32. JIN X , Newman MJ, De-Rosa S, Cooper C, et al
    A novel HIV T helper epitope-based vaccine elicits cytokine-secreting HIV-specific CD4+ T cells in a Phase I clinical trial in HIV-uninfected adults.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
33. WALKER LE , Vang L, Shen X, Livingston BD, et al
    Design and preclinical development of a recombinant protein and DNA plasmid mixed format vaccine to deliver HIV-derived T-lymphocyte epitopes.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
34. STEERS NJ , Peachman KK, McClain S, Alving CR, et al
    Liposome-encapsulated HIV-1 Gag p24 containing lipid A induces effector CD4+ T-cells, memory CD8+ T-cells, and pro-inflammatory cytokines.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
35. CURRAN RM , Donnelly L, Morrow RJ, Fraser C, et al
    Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
36. MALHOTRA U , Nolin J, Horton H, Li F, et al
    Functional properties and epitope characteristics of T-cells recognizing natural HIV-1 variants.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
37. KASHI VP , Jacob RA, Paul S, Nayak K, et al
    HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
38. CUKALAC T , Moffat JM, Venturi V, Davenport MP, et al
    Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2009
39. COLBY-GERMINARIO S , Rios A, Quesada J, Anderson D, et al
    HIV inactivation by cross-linking of photo-labeled anti-retroviral compounds with HIV reverse transcriptase.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
40. CENTER RJ , Wheatley AK, Campbell SM, Gaeguta AJ, et al
    Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
41. LOPEZ A , van der Lubbe N, Sanchez-Palomino S, Arnedo M, et al
    Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
42. WILDE H , Khawplod P, Hemachudha T
    Post-exposure rabies prophylaxis in patients with AIDS.
    Vaccine. 2009.
    PubMed     Text format     Related articles   
    
    
    
43. SANTRA S , Sun Y, Korioth-Schmitz B, Fitzgerald J, et al
    Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
44. EARL PL , Cotter C, Moss B, Vancott T, et al
    Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2009
45. DE GOEDE AL , Boers PH, Dekker LJ, Osterhaus AD, et al
    Characterization of recombinant influenza A virus as a vector for HIV-1 p17(Gag).
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
46. VOLTAN R , Castaldello A, Brocca-Cofano E, De Michele R, et al
    Priming with a very low dose of DNA complexed with cationic block copolymers followed by protein boost elicits broad and long-lasting antigen-specific humoral and cellular responses in mice.
    Vaccine. 2009;27:4498-507.
    PubMed     Text format     Related articles    Abstract available
    
    
    
47. TURBANT S , Martinon F, Moine G, Le Grand R, et al
    Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
48. LONG EF , Brandeau ML, Owens DK
    Potential population health outcomes and expenditures of HIV vaccination strategies in the United States.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2009
49. LIU J , Ngai N, Stone GW, Yue FY, et al
    The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
50. KANG YK , Andjelic S, Binley JM, Crooks ET, et al
    Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
51. GABITZSCH ES , Xu Y, Yoshida LH, Balint J, et al
    Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
52. HINKULA J , Walther-Jallow L, Lauren A, Makitalo B, et al
    Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
53. DAGAN R
    Serotype replacement in perspective.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
54. VALENTIN A , Chikhlikar P, Patel V, Rosati M, et al
    Comparison of DNA vaccines producing HIV-1 gag and LAMP/gag chimera in rhesus macaques reveals antigen-specific T-cell responses with distinct phenotypes.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
55. MICHELINI Z , Negri DR, Baroncelli S, Spada M, et al
    Development and use of SIV-based Integrase defective lentiviral vector for immunization.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
56. WATSON DS , Szoka FC Jr
    Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
57. CHEGE GK , Thomas R, Shephard EG, Meyers A, et al
    A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particles vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
58. MAKSAEREEKUL S , Dubie RA, Shen X, Kieu H, et al
    Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-alpha plasmids preserves global CD4 T lymphocyte function after challenge with FIV.
    Vaccine. 2009;27:3754-65.
    PubMed     Text format     Related articles    Abstract available
    
    
    
59. BENFERHAT R , Krust B, Rey-Cuille MA, Hovanessian AG, et al
    The caveolin-1 binding domain of HIV-1 glycoprotein gp41 (CBD1) contains several overlapping neutralizing epitopes.
    Vaccine. 2009;27:3620-30.
    PubMed     Text format     Related articles    Abstract available
    
    
    
60. CAPUTO A , Castaldello A, Brocca-Cofano E, Voltan R, et al
    Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration.
    Vaccine. 2009;27:3605-15.
    PubMed     Text format     Related articles    Abstract available
    
    
    
61. PUISSANT-LUBRANO B , Combadiere B, Duffy D, Wincker N, et al
    Influence of antigen exposure on the loss of long-term memory to childhood vaccines in HIV-infected patients.
    Vaccine. 2009;27:3576-83.
    PubMed     Text format     Related articles    Abstract available
    
    
    May 2009
62. TANZI E , Amendola A, Bianchi S, Fasolo MM, et al
    Human papillomavirus genotypes and phylogenetic analysis of HPV-16 variants in HIV-1 infected subjects in Italy.
    Vaccine. 2009;27 Suppl 1:A17-23.
    PubMed     Text format     Related articles    Abstract available
    
    
    
63. ORLANDO G , Beretta R, Fasolo MM, Amendola A, et al
    Anal HPV genotypes and related displasic lesions in Italian and foreign born high-risk males.
    Vaccine. 2009;27 Suppl 1:A24-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
64. GOMEZ CE , Najera JL, Sanchez R, Jimenez V, et al
    Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
    Vaccine. 2009;27:3165-74.
    PubMed     Text format     Related articles    Abstract available
    
    
    
65. ABDEL-MOTAL UM , Wigglesworth K, Galili U
    Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody.
    Vaccine. 2009;27:3072-82.
    PubMed     Text format     Related articles    Abstract available
    
    
    
66. JOHNSON TR , Rao S, Seder RA, Chen M, et al
    TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.
    Vaccine. 2009;27:3045-52.
    PubMed     Text format     Related articles    Abstract available
    
    
    
67. GANDHI RT , O'Neill D, Bosch RJ, Chan ES, et al
    A Randomized Therapeutic Vaccine Trial of Canarypox-HIV-pulsed Dendritic Cells vs. Canarypox-HIV Alone in HIV-1-infected Patients on Antiretroviral Therapy.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
68. GUDMUNDSDOTTER L , Nilsson C, Brave A, Hejdeman B, et al
    Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
69. ALINE F , Brand D, Pierre J, Roingeard P, et al
    Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic pla nanoparticles induce enhanced Cellular immune responses against hiv-1 after vaccination P24 nanoparticles induce dendritic cell function.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
70. HU N , Yu R, Shikuma C, Shiramizu B, et al
    Role of cell signaling in poxvirus-mediated foreign gene expression in mammalian cells.
    Vaccine. 2009;27:2994-3006.
    PubMed     Text format     Related articles    Abstract available
    
    
    
71. ERIK JOHNSON J , Coleman JW, Kalyan NK, Calderon P, et al
    In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation.
    Vaccine. 2009;27:2930-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
72. LIU X , Broberg E, Watanabe D, Dudek T, et al
    Genetic engineering of a modified herpes simplex virus 1 vaccine vector.
    Vaccine. 2009;27:2760-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
73. MEDAGLINI D , Olesen OF, Rappuoli R
    The European effort towards the development of mucosal vaccines for poverty-related diseases.
    Vaccine. 2009;27:2641-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
74. ALMEIDA VD , Mussi-Pinhata MM, Souza CB, Kubo CA, et al
    Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-infected pregnant women and kinetics of passively acquired antibodies in young infants.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
75. LANDRUM ML , Hullsiek KH, Ganesan A, Weintrob AC, et al
    Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: Another benefit of HAART in those with preserved CD4 count.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    April 2009
76. GELINCK LB , van den Bemt BJ, Marijt WA, van der Bijl AE, et al
    Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible.
    Vaccine. 2009;27:2469-74.
    PubMed     Text format     Related articles    Abstract available
    
    
    
77. DODET B
    Report of the Fifth AREB Meeting Ho Chi Minh City, Vietnam, 17-20 November 2008.
    Vaccine. 2009;27:2403-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
78. MCBURNEY SP , Ross TM
    Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
79. MILLER JP , Geng Y, Ng HL, Yang OO, et al
    Packaging Limits and Stability of HIV-1 Sequences in a Coxsackievirus B Vector.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
80. ETUWEWE OM , Swann N, Hollingshead S, Tolmie H, et al
    Effect of recurrent invasive pneumococcal disease on serum anti-pneumolysin IgG titres in HIV infected adults.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
81. BOSCH V , Pfeiffer T, Devitt G, Allespach I, et al
    HIV pseudovirion vaccine exposing Env "fusion intermediates"-response to immunisation in human CD4/CCR5-transgenic rats.
    Vaccine. 2009;27:2202-12.
    PubMed     Text format     Related articles    Abstract available
    
    
    
82. SIRIKWIN S , Likanonsakul S, Simakanwaradejwinyoo, Pattamadilok S, et al
    Antibody response to an eight-site intradermal rabies vaccination in patients infected with Human Immunodeficiency Virus.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    March 2009
83. VELLOZZI C , Burwen DR, Dobardzic A, Ball R, et al
    Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring.
    Vaccine. 2009;27:2114-2120.
    PubMed     Text format     Related articles    Abstract available
    
    
    
84. GOUDSMIT J , Bogaards JA, Jurriaans S, de Wolf F, et al
    WITHDRAWN: Loss of control of viremia in HIV-1 seroconverters with best prognosis and lowest viral load at setpoint.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
85. GIDDING HF , Wallace C, Lawrence GL, McIntyre PB, et al
    Australia's national Q fever vaccination program.
    Vaccine. 2009;27:2037-41.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2009
86. LONGO O , Tripiciano A, Fiorelli V, Bellino S, et al
    Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
87. LEMIALE F , Korokhov N
    Lentiviral vectors for HIV disease prevention and treatment.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
88. COURTNEY AN , Nehete PN, Nehete BP, Thapa P, et al
    Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
89. LINIGER M , Zuniga A, Morin TN, Combardiere B, et al
    Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
90. ABULAFIA-LAPID R , Afentoulis M, Vandenbark AA
    Peptide therapy for anti-CD4 autoimmunity in HIV-1 infection: Toward the development of an autoimmune animal model.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
91. YAN J , Hokey DA, Morrow MP, Corbitt N, et al
    Novel SIVmac DNA vaccines encoding Env, Pol and Gag consensus proteins elicit strong cellular immune responses in cynomolgus macaques.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
92. PARIANI E , Amendola A, Tanzi E, Zanetti A, et al
    Vaccination of people at increased risk of influenza complications in Italy: How far have we gone?
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
93. GURUNATHAN S , Habib RE, Baglyos L, Meric C, et al
    Use of predictive markers of HIV disease progression in vaccine trials.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2009
94. ANGELA LE , Guarascio P
    HIV vaccine. A short and concise query.
    Vaccine. 2009.
    PubMed     Text format     Related articles   
    
    
    
95. FRUTH U
    Considerations regarding efficacy endpoints in HIV vaccine trials: (I) Executive summary and recommendations of an expert consultation jointly organized by WHO, UNAIDS and ANRS in support of the Global HIV Vaccine Enterprise.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
96. YANG QE
    IgM, not IgG, a key for HIV vaccine.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
97. SUZUKI H , Kidokoro M, Fofana IB, Ohashi T, et al
    Immunogenicity of newly constructed attenuated vaccinia strain LC16m8Delta that expresses SIV Gag protein.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
98. SCHELL J , Rose NF, Fazo N, Marx PA, et al
    Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2008
99. OXFORD JS
    The end of the beginning: Vaccines for the next 25 years.
    Vaccine. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2008
100. SUH YS , Park KS, Sauermann U, Kim KS, et al
     Prolonged survival of vaccinated macaques after oral SIVmac239 challenge regardless of viremia control in the chronic phase.
     Vaccine. 2008.
     PubMed     Text format     Related articles    Abstract available
     
     

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: